BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27771741)

  • 1. Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report.
    Owonikoko TK; Kumar M; Yang S; Kamphorst AO; Pillai RN; Akondy R; Nautiyal V; Chatwal MS; Book WM; Sahu A; Sica GL; Ahmed R; Ramalingam SS
    Cancer Immunol Immunother; 2017 Jan; 66(1):45-50. PubMed ID: 27771741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue.
    Aguirre LE; Guzman ME; Lopes G; Hurley J
    Oncologist; 2019 Mar; 24(3):394-401. PubMed ID: 30413665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint Inhibitor-Induced Rejection of a Liver Allograft: A Combination of Acute T Cell-Mediated and Antibody-Mediated Rejection.
    Lee BT; Horwich BH; Chopra S; Ahearn A; Han HH
    Liver Transpl; 2019 Dec; 25(12):1845-1848. PubMed ID: 31408574
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor Regression and Allograft Rejection after Administration of Anti-PD-1.
    Lipson EJ; Bagnasco SM; Moore J; Jang S; Patel MJ; Zachary AA; Pardoll DM; Taube JM; Drake CG
    N Engl J Med; 2016 Mar; 374(9):896-8. PubMed ID: 26962927
    [No Abstract]   [Full Text] [Related]  

  • 5. Correlations of lymphocyte subset infiltrates with donor-specific antibodies and acute antibody-mediated rejection in endomyocardial biopsies.
    Frank R; Dean SA; Molina MR; Kamoun M; Lal P
    Cardiovasc Pathol; 2015; 24(3):168-72. PubMed ID: 25440957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe Allograft Rejection and Autoimmune Hemolytic Anemia After Anti-PD1 Therapy in a Kidney Transplanted Patient.
    Deltombe C; Garandeau C; Renaudin K; Hourmant M
    Transplantation; 2017 Sep; 101(9):e291. PubMed ID: 29633980
    [No Abstract]   [Full Text] [Related]  

  • 7. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection.
    Ong M; Ibrahim AM; Bourassa-Blanchette S; Canil C; Fairhead T; Knoll G
    J Immunother Cancer; 2016; 4():64. PubMed ID: 27777773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral immunotherapy with anti-PD-1 and TLR9 agonist induces systemic antitumor immunity without accelerating rejection of cardiac allografts.
    Dang N; Waer M; Sprangers B; Lin Y
    Am J Transplant; 2021 Jan; 21(1):60-72. PubMed ID: 32506732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy.
    Boils CL; Aljadir DN; Cantafio AW
    Am J Transplant; 2016 Aug; 16(8):2496-7. PubMed ID: 26988410
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.
    Azpilikueta A; Agorreta J; Labiano S; Pérez-Gracia JL; Sánchez-Paulete AR; Aznar MA; Ajona D; Gil-Bazo I; Larrayoz M; Teijeira A; Rodriguez-Ruiz ME; Pio R; Montuenga LM; Melero I
    J Thorac Oncol; 2016 Apr; 11(4):524-36. PubMed ID: 26845193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.
    Abdel-Wahab N; Safa H; Abudayyeh A; Johnson DH; Trinh VA; Zobniw CM; Lin H; Wong MK; Abdelrahim M; Gaber AO; Suarez-Almazor ME; Diab A
    J Immunother Cancer; 2019 Apr; 7(1):106. PubMed ID: 30992053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
    Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
    Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 receptor signaling disruption prevents cardiac allograft deterioration in mice.
    Iida S; Omoto K; Kanemitsu I; Setoguchi K; Ishida H; Tanabe K; Suzuki T; Tashiro Y; Kishimoto H; Abe R
    Exp Clin Transplant; 2012 Aug; 10(4):375-85. PubMed ID: 22758208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mobilization of T lymphocytes following cardiac transplantation. Evidence that CD4-positive cells are required for cytotoxic T lymphocyte activation, inflammatory endothelial development, graft infiltration, and acute allograft rejection.
    Bishop DK; Shelby J; Eichwald EJ
    Transplantation; 1992 Apr; 53(4):849-57. PubMed ID: 1533070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells.
    Xia G; He J; Zhang Z; Leventhal JR
    Transplantation; 2006 Dec; 82(12):1749-55. PubMed ID: 17198271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection.
    Lipson EJ; Naqvi FF; Loss MJ; Schollenberger MD; Pardoll DM; Moore J; Brennan DC
    Am J Transplant; 2020 Aug; 20(8):2264-2268. PubMed ID: 32185872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of T-cell phenotype characterization in endomyocardial biopsy fragments from human cardiac allografts.
    Higuchi ML; de Assis RV; Sambiase NV; Reis MM; Kalil J; Bocchi E; Fiorelli A; Stolf N; Bellotti G; Pileggi F
    J Heart Lung Transplant; 1991; 10(2):235-42. PubMed ID: 1674430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of acute murine cardiac allograft rejection: anti-CD4 or anti-vascular cell adhesion molecule one monoclonal antibodies block acute rejection but permit persistent graft-reactive alloimmunity and chronic tissue remodelling.
    Orosz CG; Huang EH; Bergese SD; Sedmak DD; Birmingham DJ; Ohye RG; VanBuskirk AM
    J Heart Lung Transplant; 1997 Sep; 16(9):889-904. PubMed ID: 9322138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab-induced severe rejection and graft intolerance syndrome resulting in renal allograft nephrectomy.
    Padala SA; Patel SK; Vakiti A; Patel N; Gani I; Kapoor R; Muhammad S
    J Oncol Pharm Pract; 2021 Mar; 27(2):470-476. PubMed ID: 32580640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased circulating follicular helper T cells with decreased programmed death-1 in chronic renal allograft rejection.
    Shi J; Luo F; Shi Q; Xu X; He X; Xia Y
    BMC Nephrol; 2015 Nov; 16():182. PubMed ID: 26525294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.